Overview
Shares of Biogen Inc. (NASDAQ:BIIB) dropped nearly 9% after the company released top-line results from the Phase 2 CELIA study of diranersen, an investigational therapy for Alzheimer’s disease. The program achieved a major scientific milestone by producing substantial reductions in tau biomarkers, but the study failed to meet its primary endpoint of demonstrating a dose-dependent effect on the CDR-SB, a key measure of cognitive decline. Instead, investigators observed an unexpected inverse dose response - the lowest dose produced the strongest clinical effect while higher doses yielded diminishing returns.
Primary clinical and biomarker results
Diranersen did not confirm a dose-dependent benefit on the CDR-SB. Rather than a linear improvement with increasing dose, the trial revealed what sponsors described as a "ceiling effect," with the lowest dose showing the clearest clinical improvement.
| Dose Regimen | CDR-SB (Clinical Decline Slowing) | ADAS-Cog13 (Cognitive Slowing) | MMSE (Mental State Improvement) |
|---|---|---|---|
| 60 mg (Every 6 Mos) | 26% | 42% | 50% |
| 115 mg (Every 6 Mos) | 14% | 32% | 34% |
| 115 mg (Every 3 Mos) | 9% | 29% | 38% |
On the biomarker front, diranersen demonstrated large pharmacodynamic effects. The drug produced a 50% to 65% reduction in cerebrospinal fluid (CSF) total tau and significant reductions in brain tau pathology across all doses tested. The agent targets MAPT mRNA and appears to reduce both intracellular and extracellular tau.
Safety and tolerability
The safety profile diverged by dose. The 60 mg dose - the dose that generated the most favorable clinical signal - was well tolerated, with serious adverse events occurring at a rate balanced with placebo at 13%. In contrast, the 115 mg arms experienced high discontinuation rates of 20% to 25%, driven primarily by severe procedure-related pain and confusional states.
Notably, diranersen showed 0% ARIA - brain swelling or bleeding - in the trial. Existing anti-amyloid therapies have real-world ARIA rates of roughly 10%, so the absence of ARIA in this study expands the apparent therapeutic window for diranersen compared with monoclonal antibody approaches such as Leqembi and Kisunla.
Market reaction and analyst perspectives
Market participants reacted sharply to the dosing conundrum and the stock fell in response. Analysts have split assessments of the readout.
- Morgan Stanley (Terence Flynn) said the 60 mg efficacy landed at the lower end of expectations and emphasized that management's inability to explain the inverse dose response is the main factor pressuring the stock.
- William Blair (Myles Minter) acknowledged the modest clinical effect at the lower dose but argued the data demonstrate that diranersen may be superior to monoclonal antibody strategies, interpreting intracellular tau knockdown as the correct mechanistic path.
- Jefferies (Andrew Tsai) offered a more constructive read, noting that the 60 mg dose's 26% slowing on CDR-SB aligns with the 23% to 27% slowing observed in trials of Leqembi and Kisunla, and suggesting the possibility of an optimal ceiling for tau reduction.
Path forward
Despite missing the prespecified primary endpoint, the combination of strong biomarker responses and the favorable low-dose safety signal provide Biogen with a pathway to advance diranersen into Phase 3 testing. Company management faces pressure to resolve the dosing paradox and refine patient selection criteria before locking in final Phase 3 design choices.
Bottom line
Diranersen's Phase 2 results present a mixed picture: clear biological activity against tau and a clean ARIA profile at a low dose, offset by an unanticipated inverse dose-response and tolerability problems at higher doses. The data give Biogen a technical route to a pivotal study, but they also raise questions that must be answered to optimize dose selection and trial design.